Company overview
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights in the Netherlands and internationally. The company offers primary sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, such as kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, such as assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables, such as short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments; bioinformatics solutions; and custom laboratory and genomic services. The company provides software-as-a-service. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
Daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-08. TTM means trailing twelve months. Use the market date when comparing QGEN with another company.
| Daily close (USD) | $44.53 |
| Market capitalization (USD) | $9,195,222,350 |
| Price / earnings (TTM) | 21.64 |
| Price / book | 2.43 |
No matching rows. Clear the filter to see all records.
Read QGEN's valuation metrics
Company size
QIAGEN N.V.'s recorded market capitalization is $9,195,222,350. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
QGEN's recorded P/E is 21.64: about $21.64 of share price for each $1 of trailing annual earnings per share. Compare that multiple with earnings growth and companies in the same business.
Price relative to book equity
QGEN's recorded price-to-book ratio is 2.43. That compares its market equity value with recorded book equity. Examine its business and balance sheet to understand why those values differ.
Research QIAGEN N.V. with Aurora
Use the snapshot above to ask a specific question about QGEN. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow QGEN's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.